Drug Approval | January 08, 2026
GSK’s Exdensur wins Japanese nod for severe asthma
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
DengiAll will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
Biotium reports that GlycoLiner Labelling is fully covalent and compatible with standard fixation and permeabilization protocols
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
Subscribe To Our Newsletter & Stay Updated
